trending Market Intelligence /marketintelligence/en/news-insights/trending/vjfxst9go7a139sbnwn_sq2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Pfizer acquires AstraZeneca's antibiotics business

LK Bennett Bankruptcy Case Study

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry


Pfizer acquires AstraZeneca's antibiotics business

Pfizer Inc. acquired AstraZeneca PLC's late-stage antibiotics business for an upfront payment of $550 million.

AstraZeneca will receive another $175 million in January 2019 and is eligible for $250 million in commercial, manufacturing and regulatory milestones.

Pfizer will also pay up to $600 million in sales-related payments as well as recurring, double-digit royalties on sales of Zavicefta and ATM-AVI in certain markets.